433303-94-7

Usage

Chemical class

Piperazine derivatives It belongs to a group of compounds derived from piperazine, a heterocyclic amine.

Heterocyclic compound

Contains a piperazine ring and a benzo[b]thiophene ring The molecule features two heterocyclic rings fused together, which may contribute to its pharmacological properties.

Potential pharmacological and biological activities

May have an affinity for certain receptors in the central nervous system This suggests that the compound could interact with specific receptors, potentially leading to therapeutic effects.

Applications in medicinal chemistry research

Development of new drugs The compound's structure and potential receptor interactions make it a candidate for further research in the development of novel therapeutic agents.

Possible treatment of neurological and psychiatric disorders

Due to its potential receptor interactions The compound's structure and properties may make it useful for the treatment of various conditions related to the central nervous system.

Further research needed

To fully understand its properties and potential applications More studies are required to determine the compound's exact mechanisms of action, safety, and efficacy in various therapeutic contexts.

Molecular weight

Approximately 268.38 g/mol Provides an estimate of the compound's mass, which can be useful for determining dosages and concentrations in research and clinical settings.

Solubility

May vary depending on the solvent The compound's solubility in different solvents can impact its formulation and administration in potential therapeutic applications.

Stability

May be influenced by factors such as temperature, pH, and exposure to light Understanding the stability of the compound is crucial for its storage, handling, and long-term use in research and clinical settings.

Upstream product

• 110-85-0 piperazine 
• 4923-87-9 5-bromobenzo[b]thiophene 
• 4965-26-8 5-nitrobenzo[b]thiophene 
• 20532-28-9 5-aminobenzo[b]thiophene 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Relevant academic research and scientific papers

Synthesis of trans-2-Substituted Cyclopropylamines from α-Chloroaldehydes

Cyclopropylamines are prevalent in pharmaceuticals and agrochemicals. Herein, we report the synthesis of trans-2-substituted cyclopropylamines in high diastereoselectivity from readily available α-chloroaldehydes. The reaction proceeds via trapping of an electrophilic zinc homoenolate with an amine followed by ring closure to generate the cyclopropylamine. We have also observed that cyclopropylamine cis/trans-isomerization occurs in the presence of zinc halide salts and that this process can be turned off by the addition of a polar aprotic cosolvent.

Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT1A receptors

It has been proposed that 5-HT1A receptor antagonists augment the antidepressant efficacy of selective serotonin (5-HT) reuptake inhibitors. In a search toward new and efficient antidepressants, 1-(aryl)-3-[4-arylpiperazin-1-yl]-1-propane molecular hybrids were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor affinity. The design was based in coupling structural moieties related to inhibition of serotonin reuptake, such as benzo[b]-thiophene derivatives to arylpiperazines, typical 5-HT1A receptor ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and at 5-HT1A receptors. Molecular modeling studies predicted the pharmacophore elements required for high affinity binding and the features that enable to discriminate between agonist, partial agonist, or antagonist action at 5-HT1A receptors and 5-HT transporter inhibition. Solvent interactions in desolvation prior to the binding step along with enthalpy and enthropy compensations might be responsible to explain agonist, partial agonist, and antagonist character. Hydrogen-bonding capability seems to be important to break hydrogen interhelical hydrogen bonds or alternatively to form other bonds upon ligand binding. Partial agonists and antagonists are unable to do this as the full agonist, which interacts closely by long-range forces or directly. The compounds showing the higher affinity at both the 5-HT transporter (Ki 1A receptors (Ki 35S]GTPγS binding or to antagonize 8-hydroxy-2-di-n-propylamino-tetralin (8-OH-DPAT)-stimulated [35]GTPγS binding to rat hippocampal membranes, an index of agonist/antagonist action at 5-HT1A receptors, respectively. Compound 8g exhibited agonist activity (EC50 = 30 nM) in this assay, whereas compounds 7g and 8h,i behaved as weak partial agonists and 7h-j and 8j,1 antagonized the R(+)-8-OH-DPAT-stimulated GTPγS binding. Functional characterization was performed by measuring the antagonism to 8-OH-DPAT-induced hypothermia in mice.